Predictive Biosciences announced that the Company will be presenting its novel Multi-Analyte Diagnostic Readout (MADR™) approach to the development of a non-invasive, urinary biomarker based assay for the detection of bladder cancer during the 2010 Genitourinary Cancers Symposium (GU Symposium), being held March 5-7 in San Francisco. The GU Symposium is co-sponsored by the American Society of Clinical Oncology (ASCO), the American Society for Radiation Oncology (ASTRO) and the Society of Urologic Oncology (SUO)… (Source: Health News from Medical News Today)

Further information:

Article source

Related posts:

1. Proton beam therapy shows encouraging long-term outcome for patients with locally advanced sinonasal cancers
2. Accelerated radiation therapy reduces toxicity in patients with advanced head and neck cancers
3. The ASCO Cancer Foundation Awards $25,000 To Young Researchers For Important Contributions To Genitourinary Cancers Research
4. Studies Presented At 2010 Genitourinary Cancers Symposium Advance Management, Treatment Of Prostate And Bladder Cancers
5. Larynx preservation treatments result in low instance of severe voice disability, nutritional dysfunction